SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?

Dario Pitocco; Linda Tartaglione; Luca Viti; Mauro Di Leo; Alfredo Pontecorvi; Salvatore Caputo

doi:10.1016/j.diabres.2020.108162

SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?

Dario Pitocco, Linda Tartaglione, Luca Viti, Mauro Di Leo, Alfredo Pontecorvi, Salvatore Caputo

IRCCS Fondazione Policlinico Universitario A. Gemelli

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 COVID-19. It has been hypothesized that DPP4 inhibition, a therapy currently available for type 2 diabetes, might represent a target for decreasing the risk of the acute respiratory complications of the COVID-19 infection but (1) lack of demonstration of SARS-CoV2 binding to DPP4 (2) possible protective role of sDPP4 in Middle East respiratory Syndrome (MERS-CoV) (3) demonstrated inhibition and downregulation of DPP4 by HIV1 and MERS-CoV and (4) not exclusive role of the receptor binding in tropism of the Coronavirus family, support that DPP4 inhibition at present doesn't represent a plausible approach to mitigate COVID-19.

Original language	English
Article number	108162
Journal	Diabetes Research and Clinical Practice
Volume	163
DOIs	https://doi.org/10.1016/j.diabres.2020.108162
Publication status	Published - May 2020

Keywords

ACE 2
COVID 19
Diabetes
DPP4

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Endocrinology

Access to Document

10.1016/j.diabres.2020.108162

Cite this

@article{62959e8d58a7491fa0d06c53718c07c3,

title = "SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?",

abstract = "Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 COVID-19. It has been hypothesized that DPP4 inhibition, a therapy currently available for type 2 diabetes, might represent a target for decreasing the risk of the acute respiratory complications of the COVID-19 infection but (1) lack of demonstration of SARS-CoV2 binding to DPP4 (2) possible protective role of sDPP4 in Middle East respiratory Syndrome (MERS-CoV) (3) demonstrated inhibition and downregulation of DPP4 by HIV1 and MERS-CoV and (4) not exclusive role of the receptor binding in tropism of the Coronavirus family, support that DPP4 inhibition at present doesn't represent a plausible approach to mitigate COVID-19.",

keywords = "ACE 2, COVID 19, Diabetes, DPP4",

author = "Dario Pitocco and Linda Tartaglione and Luca Viti and {Di Leo}, Mauro and Alfredo Pontecorvi and Salvatore Caputo",

year = "2020",

month = may,

doi = "10.1016/j.diabres.2020.108162",

language = "English",

volume = "163",

journal = "Diabetes Research and Clinical Practice",

issn = "0168-8227",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - SARS-CoV-2 and DPP4 inhibition

T2 - Is it time to pray for Janus Bifrons?

AU - Pitocco, Dario

AU - Tartaglione, Linda

AU - Viti, Luca

AU - Di Leo, Mauro

AU - Pontecorvi, Alfredo

AU - Caputo, Salvatore

PY - 2020/5

Y1 - 2020/5

N2 - Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 COVID-19. It has been hypothesized that DPP4 inhibition, a therapy currently available for type 2 diabetes, might represent a target for decreasing the risk of the acute respiratory complications of the COVID-19 infection but (1) lack of demonstration of SARS-CoV2 binding to DPP4 (2) possible protective role of sDPP4 in Middle East respiratory Syndrome (MERS-CoV) (3) demonstrated inhibition and downregulation of DPP4 by HIV1 and MERS-CoV and (4) not exclusive role of the receptor binding in tropism of the Coronavirus family, support that DPP4 inhibition at present doesn't represent a plausible approach to mitigate COVID-19.

AB - Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 COVID-19. It has been hypothesized that DPP4 inhibition, a therapy currently available for type 2 diabetes, might represent a target for decreasing the risk of the acute respiratory complications of the COVID-19 infection but (1) lack of demonstration of SARS-CoV2 binding to DPP4 (2) possible protective role of sDPP4 in Middle East respiratory Syndrome (MERS-CoV) (3) demonstrated inhibition and downregulation of DPP4 by HIV1 and MERS-CoV and (4) not exclusive role of the receptor binding in tropism of the Coronavirus family, support that DPP4 inhibition at present doesn't represent a plausible approach to mitigate COVID-19.

KW - ACE 2

KW - COVID 19

KW - Diabetes

KW - DPP4

UR - http://www.scopus.com/inward/record.url?scp=85083893286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85083893286&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2020.108162

DO - 10.1016/j.diabres.2020.108162

M3 - Comment/debate

C2 - 32335097

AN - SCOPUS:85083893286

SN - 0168-8227

VL - 163

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

M1 - 108162

ER -

SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this